Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 1/20 | 0.32 |
| ▸ | CTSB | P07858 | 1/20 | 0.32 |
| ▸ | CTSS | P25774 | 1/20 | 0.32 |
| ▸ | CTSC | P53634 | 1/20 | 0.32 |
| ▸ | ANPEP | P15144 | 2/20 | 0.32 |
| ▸ | RNPEP | Q9H4A4 | 2/20 | 0.32 |
| ▸ | DNPEP | Q9ULA0 | 1/20 | 0.32 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.32 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.31 |
| ▸ | FOLH1 | Q04609 | 3/20 | 0.31 |
| ▸ | BIRC2 | Q13490 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20465427 | 1.00 | CTSL (0.32) | CTSLCTSBCTSSCTSCANPEP | |
| SCHEMBL20465433 | 0.97 | CTSB (0.37) | CTSLCTSBCTSSCTSCANPEP | |
| SCHEMBL20465429 | 0.88 | L3MBTL1 (0.39) | CTSLCTSBCTSSCTSCANPEP | |
| SCHEMBL29465612 | 0.88 | L3MBTL1 (0.39) | CTSLCTSBCTSSCTSCANPEP | |
| SCHEMBL18452348 | 0.88 | L3MBTL1 (0.39) | CTSLCTSBCTSSCTSCANPEP | |
| SCHEMBL20468541 | 0.88 | ANPEP (0.32) | ANPEPRNPEPDNPEPERAP2SCN9A | |
| SCHEMBL30948742 | 0.86 | PSMB5 (0.35) | CTSLCTSBCTSSCTSCANPEP | |
| SCHEMBL18452391 | 0.85 | FOLH1 (0.43) | ANPEPRNPEPDNPEPERAP2FOLH1 | |
| SCHEMBL20465424 | 0.85 | FOLH1 (0.43) | ANPEPRNPEPDNPEPERAP2FOLH1 | |
| SCHEMBL18452352 | 0.85 | CTSL (0.39) | CTSLCTSBCTSSCTSCERAP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112920092-B | Prodrugs of glutamine analogues | 约翰霍普金斯大学 | 2024-04-26 | — | — | CN | disclosed |
| US-11926640-B2 | Prodrugs of glutamine analogs | THE JOHNS HOPKINS UNIVERSITY (US) | 2024-03-12 | — | — | US | disclosed |
| EP-3328827-B1 | PRODRUGS OF GLUTAMINE ANALOGS | UNIV JOHNS HOPKINS (US) | 2023-07-05 | — | — | EP | disclosed |
| US-20210206787-A1 | PRODRUGS OF GLUTAMINE ANALOGS | Ústav organické chemie a biochemie AV CR, v.v.i. (CZ) | 2021-07-08 | — | — | US | disclosed |
| CN-112920092-A | Prodrugs of glutamine analogs | 约翰霍普金斯大学 | 2021-06-08 | — | — | CN | disclosed |
| US-10954257-B2 | Prodrugs of glutamine analogs | THE JOHNS HOPKINS UNIVERSITY (US) | 2021-03-23 | — | — | US | disclosed |
| CN-108290827-B | Prodrugs of glutamine analogs | 约翰霍普金斯大学 | 2021-01-01 | — | — | CN | disclosed |
| US-10738066-B2 | Prodrugs of glutamine analogs | THE JOHNS HOPKINS UNIVERSITY (US) | 2020-08-11 | — | — | US | disclosed |
| US-20190315784-A1 | PRODRUGS OF GLUTAMINE ANALOGS | DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C), AS COLLATERAL AGENT | 2019-10-17 | — | — | US | disclosed |
| US-20190315783-A1 | PRODRUGS OF GLUTAMINE ANALOGS | DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C), AS COLLATERAL AGENT | 2019-10-17 | — | — | US | disclosed |
| US-10336778-B2 | Prodrugs of glutamine analogs | THE JOHNS HOPKINS UNIVERSITY (US) | 2019-07-02 | — | — | US | disclosed |
| US-20180222930-A1 | PRODRUGS OF GLUTAMINE ANALOGS | DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C), AS COLLATERAL AGENT | 2018-08-09 | — | — | US | disclosed |
| US-20180222930-A1 | PRODRUGS OF GLUTAMINE ANALOGS | DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C), AS COLLATERAL AGENT | 2018-08-09 | — | — | US | disclosed |
| EP-3328827-A1 | PRODRUGS OF GLUTAMINE ANALOGS | The Johns Hopkins University (US) | 2018-06-06 | — | — | EP | disclosed |
| WO-2017023774-A9 | PRODRUGS OF GLUTAMINE ANALOGS | THE JOHNS HOPKINS UNIVERSITY (US) | 2017-11-23 | — | — | WO | disclosed |
| WO-2017023774-A1 | PRODRUGS OF GLUTAMINE ANALOGS | THE JOHNS HOPKINS UNIVERSITY (US) | 2017-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210206787-A1 | PRODRUGS OF GLUTAMINE ANALOGS | GLUL, GLS, GLS2 | CTSL 1610/4885CTSB 4267/4885CTSS 3579/4885 |
| US-10738066-B2 | Prodrugs of glutamine analogs | GLUL, GLS, GLS2 | CTSL 967/4885CTSB 3586/4885CTSS 2978/4885 |
| US-11926640-B2 | Prodrugs of glutamine analogs | GLUL, GLS, GLS2 | CTSL 967/4885CTSB 3586/4885CTSS 2978/4885 |
| US-20190315783-A1 | PRODRUGS OF GLUTAMINE ANALOGS | GLUL, GLS, GLS2 | CTSL 967/4885CTSB 3586/4885CTSS 2978/4885 |
| US-10336778-B2 | Prodrugs of glutamine analogs | GLUL, GLS, GLS2 | CTSL 967/4885CTSB 3586/4885CTSS 2978/4885 |
| US-10954257-B2 | Prodrugs of glutamine analogs | GLUL, GLS, GLS2 | CTSL 967/4885CTSB 3586/4885CTSS 2978/4885 |
| US-20180222930-A1 | PRODRUGS OF GLUTAMINE ANALOGS | GLUL, GLS, GLS2 | CTSL 967/4885CTSB 3586/4885CTSS 2978/4885 |
| US-20190315784-A1 | PRODRUGS OF GLUTAMINE ANALOGS | GLUL, GLS, GLS2 | CTSL 967/4885CTSB 3586/4885CTSS 2978/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.